Benzinga | Nov 4, 2020 09:17AM EST

CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies Accepted For Plenary Presentation At 62nd American Society Of Hematology Meeting And Exposition

CRISPR/Cas9 Gene-Editing Therapy CTX001(tm) for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies has been accepted for an oral presentation during the Plenary Scientific Session at the annual ASH Meeting and Exposition, which will take place virtually from December 5-8, 2020. Haydar Frangoul, M.D., Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcare's TriStar Centennial Medical Center, will deliver the presentation on behalf of all the authors on December 6, 2020.